Seasonal Affective Disorder Therapeutics Industry Radiant Growth on the Horizon, Anticipated to Achieve US$ 1.1 Billion by 2028-FMI Report

The research states that SSRIs, or selective serotonin reuptake inhibitors, are often prescribed drugs for the treatment of seasonal affective disorder. In the market for seasonal affective disorder treatments industry, there are numerous branded and generic drugs accessible, however Buproban and Citalopram continue to sell at a comparatively greater rate. FMI attributes this supremacy to …

Seasonal Affective Disorder Therapeutics industry is projected to US$ 1.1 Billion by 2028

The seasonal affective disorder (SAD) therapeutics market The market for treatments for seasonal affective disorder is expected to grow at a CAGR of 4.3% from 2022 to 2028. The market is currently valued at US$ 848.2 million and is expected to reach US$ 1.1 billion by the end of 2028. according to a recent intelligence report …